Additionally, we explored the role of LepR+ MSCs and the ROCK1 signaling pathway in the pathogenesis of BPH, while also validating the potential of ROCK1 as a therapeutic target. The gene discussed is ROCK1; the disease is benign prostatic hyperplasia.